Editing Amgen (section)

=== 2000-2014 ===
Binder was succeeded as CEO by [[Kevin W. Sharer]] in 2000.<ref>{{Cite web |title=Amgen names new CEO - May 11, 2000 |url=https://money.cnn.com/2000/05/11/news/amgen/index.htm |access-date=2024-11-04 |website=money.cnn.com}}</ref> Robert A. Bradway became Amgen's president and chief executive officer in May 2012, following Sharer's retirement.<ref name="Amgen-May-2012-8-K">{{cite web|url=http://edgar.secdatabase.com/1218/119312512245437/filing-main.htm |title=Amgen, Form 8-K, Current Report, Filing Date May 24, 2012 |publisher=secdatabase.com |access-date =Jan 8, 2013}}</ref>

In March 2011, Amgen acquired a manufacturing facility near Dublin, Ireland, in March.<ref>{{cite news |date=11 March 2011 |title=Amgen to buy Pfizer plant |url=https://www.irishtimes.com/business/health-pharma/amgen-to-buy-pfizer-plant-1.873076 |access-date=10 August 2022 |newspaper=The Irish Times |language=en}}</ref>

Amgen also opened an affiliate in China in 2013.<ref>{{cite news |last1=Becker |first1=Zoey |date=27 June 2022 |title=Amgen partners with Fosun to bring Otezla, Parsabiv to patients in China |url=https://www.fiercepharma.com/pharma/amgen-partners-fosun-pharma-bring-psoriasis-chronic-kidney-disease-medicines-country |work=Fierce Pharma |language=en}}</ref><ref>{{cite news |last1=Philippidis |first1=Alex |date=1 November 2019 |title=Amgen Expands China Presence, Cancer R&D with $2.7B BeiGene Collaboration |url=https://www.genengnews.com/news/amgen-expands-china-presence-cancer-rd-with-2-7b-beigene-collaboration/ |access-date=11 August 2022 |work=GEN - Genetic Engineering and Biotechnology News}}</ref>

In November 2014 the company announced it was halting all trials of [[rilotumumab]] in advanced [[gastric cancer]] patients after one of the trials found more deaths in those who took the compound with chemotherapy, than those without.<ref>{{cite web |date=24 November 2014 |title=GEN - News Highlights:Amgen Halts Rilotumumab Trials in Advanced Gastric Cancer |url=http://www.genengnews.com/gen-news-highlights/amgen-halts-rilotumumab-trials-in-advanced-gastric-cancer/81250637/ |work=GEN}}</ref> Later in the same week, the company in conjunction with [[AstraZeneca]] reported positive results for [[brodalumab]] in a Phase III trial comparing the compound with [[ustekinumab]] and a [[placebo]] in treating [[psoriasis]].<ref>{{cite web |title=GEN - News Highlights:Brodalumab's No Turkey in Phase III: Amgen and AstraZeneca |url=http://www.genengnews.com/gen-news-highlights/brodalumab-s-no-turkey-in-phase-iii-amgen-and-astrazeneca/81250645/ |work=GEN}}</ref> In the same month, construction was completed on Amgen's next-generation biomanufacturing facility in Singapore.<ref>{{cite news |last1=Brennan |first1=Zachary |date=21 November 2014 |title=Amgen launches $200m biomanufacturing facility in Singapore |url=https://www.biopharma-reporter.com/Article/2014/11/21/Amgen-launches-200m-biomanufacturing-facility-in-Singapore |access-date=11 August 2022 |work=BioPharma-Reporter}}</ref> Blincyto ([[blinatumomab]]) was approved by the FDA in December of that year.<ref>{{cite journal |last1=Przepiorka |first1=Donna |last2=Ko |first2=Chia-Wen |last3=Deisseroth |first3=Albert |last4=Yancey |first4=Carolyn L. |last5=Candau-Chacon |first5=Reyes |last6=Chiu |first6=Haw-Jyh |last7=Gehrke |first7=Brenda J. |last8=Gomez-Broughton |first8=Candace |last9=Kane |first9=Robert C. |last10=Kirshner |first10=Susan |last11=Mehrotra |first11=Nitin |last12=Ricks |first12=Tiffany K. |last13=Schmiel |first13=Deborah |last14=Song |first14=Pengfei |last15=Zhao |first15=Ping |date=15 September 2015 |title=FDA Approval: Blinatumomab |url=https://pubmed.ncbi.nlm.nih.gov/26374073/ |journal=Clinical Cancer Research |volume=21 |issue=18 |pages=4035–4039 |doi=10.1158/1078-0432.CCR-15-0612 |issn=1557-3265 |pmid=26374073 |s2cid=207687724 |access-date=11 August 2022 |last16=Zhou |first16=Qing |last17=Farrell |first17=Ann T. |last18=Pazdur |first18=Richard}}</ref><ref>{{cite news |date=15 December 2014 |title=FDA Approves Blinatumomab to Treat Rare Form of Acute Lymphoblastic Leukemia |url=https://ascopost.com/issues/december-15-2014/fda-approves-blinatumomab-to-treat-rare-form-of-acute-lymphoblastic-leukemia/ |access-date=11 August 2022 |work=The ASCO Post |language=en}}</ref>

Amgen's Thousand Oaks staff in 2022 numbered approximately 5,000<ref>{{cite news |last1=Biasotti |first1=Tony |date=9 April 2022 |title=In Thousand Oaks, biotech execs discuss industry's 'rising tide,' lament area's lack of housing |url=https://www.pacbiztimes.com/2022/04/08/in-thousand-oaks-biotech-execs-discuss-industrys-rising-tide-lament-areas-lack-of-housing/ |access-date=19 September 2022 |work=Pacific Coast Business Times}}</ref> (8.5% of total city employment)<ref>{{cite news |date=30 June 2021 |title=Annual Comprehensive Financial Report |url=https://www.toaks.org/home/showpublisheddocument?id=39338 |access-date=19 September 2022 |work=City of Thousand Oaks, California |page=156}}</ref> and included hundreds of scientists, making Amgen the largest employer in [[Ventura County, California|Ventura County]].<ref name="Baker, Pam 2002 Page 37" /><ref>{{cite web |date=16 February 2018 |title=Biotech giant Amgen has big plans for new plant |url=https://www.mpacorn.com/articles/biotech-giant-amgen-has-big-plans-for-new-plant/ |website=Moorpark Acorn}}</ref>